INTRODUCTION
Amino acids and peptides are the most potent components of food in stimulating gastric acid secretion (1) Received for publication 10 Jutne 1977 and in revised form 19 September 1977. elicit acid secretion by at least five mechanisms.
First, these meals cause gastric distention, which elicits secretion by stimulating cholinergic reflexes in the body and fuindus of the stomach (2) . Secoid, amino acids and peptides stimulate endogenous release of various species of gastrin from the antrum and small intestine and thereby cause a rise in the circulating concentration of these secretogogues (3, 4) . Third, amino acids in the gastric lumen of animals can react directly with parietal cells to induce acid secretion (5) . Fourth, upon entering the small intestine, peptides and amino acids may release nongastrin acid secretogogues from intestinal endocrine cells ("intestinal phase") (6, 7) . Fifth, amino acids given intravenously stinmulate acid secretion without releasing gastrin (7) . To what extent these mechanisms are involved in the human acid secretory response to meals containing aiiiino acids is unknown. For example, although intragastric amino acids release gastrin and stimtulate acid secretion, it has never been demonstrated that the rise in circulating gastrin concentration is responsible for any of the acid secretory response to amino acids. It was the purpose of these experiments to determine whether the rise in circulating gastrin heptadecapeptide (G-17)1 concentration can account for anly or all of the acid secretory response to mixed aminiilo acids in man.
METHODS
Overview of methods anid rationale. Anl amino acid solution continuously infused into the stomach stimulated acid secretion and led to a rise in plasma G-17 concentration. As a control, saliine continuously infuseci into the stomach stimulated acid secretion (though less than amino acids) but did not cause a rise in plasma G-17 concentrationi. On separate days, several i.v. doses of G-17-I were superimposed 'Abbreviatiotn used in this paper: G-17, gastrin heptadecapeptide.
The Joturnal of Clinical Investigation Voltume 61 Februiary 1978 -308-313 on the intragastric saline infusion; the resulting plasma G-17 concentration was related graphically to the acid secretory response. From this plot we determined how much acid secretion could have resulted from the rise in plasma G-17 concentration that was associated with intragastric amino acid infrision. This value was then compared with observed acid secretion in response to amino acids.
Subjects. Eight healthy subjects with no history of gastrointestinal disorder were each studied on three mornings, and experiments were performed in random order. Five subjects were men and three were women, with a mean age of 29 yr (range 22-45 yr). Basal acid output and peak acid output to 0.04 mg/kg histamine acid phosphate subcutaneously were 2.1±0.7 and 27.9±+1.7 (mean+SEM) mleq/h, respectively. No subject was taking any medication, and all gave written informed consent.
Inztubatiotn anid meeasuremiienit of acid secretiont. In all experiments a radio-opaque triple-lumen nasogastric tube was used. Tubes 1 and 3 terminated 14 cm proximal to the tip of tube 2. After a 10-h fast, the triple-lumen tube was positioned under fluoroscopic guidance with the tip of tube 2 in the gastric antrum. Through tube 1, either an amino acid or saline solution at pH 5.0 was infused into the stomach, and acid secretion was measured by in vivo intragastric titration. Every 3 min a gastric sample was aspirated through ttibe 2. pH was determined and the sample immediately returned to the stomach. Through tube 3, 0.5 N sodium bicarbonate was infused as needed to maintain gastric pH at 5 .0. The number of milliequivalents of bicarbonate added is equal to the number of'milliequivalents of acid secreted (8) .
Intragastric saline and amino acid itnfusion. To initiate the experiment, we injected 200 ml of saline (300 mosmol/ kg), adjusted to pH 5.0, into the stomach as a bolus, and a constant intragastric saline infusion was then begun at a rate of 400 mIl/h (Brinkman Peristaltic Pump, Desaga, Inc., Heidelberg, West Germany). After 90 min, intragastric saline infusion was stopped, the stomach emptied, and the volume recorded. At this point, a volume of mixed amino acid solution (300 mosmol/kg) (casein hvdrolysate, Stuart Pharmaceuticals Div., Wilmingtoni, Del.) equial to the volume just emptied was injected into the stomach and a constant intragastric amino acid infusion was begun at a rate of 400 nil/h. Intragastric amino acid infusioni was continued for 180 min (i.e., from 90 to 270 miii). Gastric volume was also nieasured by aspiration and reinifusioni at 180 min and by aspiration at 270 miii. During the 270-min experiment, 0.15 NI NaCl was slowly infused intravenously.
In?travenous G-17 infusiont. On two additional mornings, G-17 dose-response studies were carried out while the stomach was being continuously infused with saline for the entire 270-min experiment. As described above, a 200-ml saline bolus was injected into the stoniiach and saline was infused intragastrically at 400 ml/h. During a 90-min control period, 0.15 XI NaCl was slowly infused intravenously. After the control period, a 90-min i.v. infusion of one of four G-17-I doses was begun. At 180 min, a secoiid 90-min i.v. infuision of another of the four G-17-I doses was initiated. Each subject, therefore, received four different G-17-I doses over two niorninigs. Gastric volume was measured as above at 90, 180, and 270 miii.
Preparatiotn anid dosage of G-17-I. Synthetic human G-17-I (Imperial Chemical Induistries, Ltd., Cheshire, Eiigland) was diluted to 25 ml with 0.15 MI NaCl in 1% humiian albuniin and infused intravenously by a Havard syringe punip (Harvard Apparattus Co., Inc., Millis, MIass.). Doses were 4.0, 10.0, 25.0, and 62.5 pmol/kg h and were given in ranidomii order. These doses were selected because they seemed likel) to produce plasma G-17 concentrations in the physiologic range. Since the plasma half-life of G-17-I is approximately 6 min, a steady plasma G-17 concentration should be reached within 30-45 min (3) . For this reason, plasma G-17 concentration was measured every 15 min during the latter half of each 90-min i.v. infusion of G-17 or saline.
Plasma G-1 7 and gastrin measurement. Through a separate indwelling 19-gauge needle, 12 ml of venous blood was drawn into oxalate tubes from the arm opposite the i.v. G-17 or saline infusion. Plasma, obtained immediately by centrifugation, was stored at -20°C until assayed. Plasma G-17 concentration was measured by radioimmunoassay using L6, an antibody which has almost absolute specificity for heptadecapeptide gastrins I and II. The characteristics of this antibody have been described in detail recently (9) . Coded samples were run in duplicate at 1: 10 dilution and read against a standard curve of G-17 diluted in 5% gastrin-free seruni prepared by charcoal extraction, and then samples were decoded.
RESULTS
Acid secretion and plasma G-1 7 concentration during intragastric saline and amino acid infusion. As shown in Fig. 1 Thus, mean acid secretion increased 3.2 meq/15 min and plasma G-17 concentration increased 13 pmol/liter with -amino acid infusion. In the eight individual subjects, acid secretion in response to amino acids (expressed as a percent of peak histamine response) was correlated closely with the concomitant rise in plasma G-17 concentration (r = 0.92, P < 0.001).
Acid secretion and plasma G-1 7 concentration
Role of Gastrint Heptadecapeptide in Gastric Acid Secretion (Table I) . The relationship between rise in plasma G-17 concentration during i.v. G-17-I infusion and the corresponding rise in acid secretion, in milliequivalents per hour, is shown in Fig. 3 . Each point represents the mean rise (+SEM) for each G-17-I dose. From this curve, the anticipated acid secretory response to a given rise in plasma G-17 concentration can be determined.
Predicted acid secretory response to rise in plasma G-1 7 concentration induced by amino acids. Plasma G-17 concentration rose 13 pmol/liter during intragastric amino acid infusion (Fig. 1) . As shown by the dashed line in Fig. 3, this DISCUSSION It was the purpose of these experiments to deterIminie the potential role of G-17 in the human acid secretory response to meals containing amino acids. A constant intragastric infuLsion of mixed amino acids was employed instead of a normal eaten meal for several reasons. First, when a meal is eaten, G-17 levels rise rapidly and begin to fall within 30 min (9) . Second, during and after a meal, gastric volume and the volume, pH, and osmolarity of chyme entering the small intestine are not constant. Third, food also contains fat and carbohydrate, which can release inhibitors of acid secretioin from the small intestine. Because of these complex changes occurring during and after eating, it is impossible to determine what role a par-ticular stimulant, such as G-17, plavs in the overall secretory response.
Intragastric infusion of an isotonic mixed amino acid solution produced plasma G-17 concentrations * The difference between rate of acid secretioin during G-17 infusion and saline control was significant (P < 0.05).
The difference between plasma G-17 concentrationi during G-17 infusion or saline control was not significant (P > 0.6).
Role of Gastrin Heptadecapeptide in Gastric Acid Secretion and acid secretory rates that were stable. Likewise, continuous i.v. infusion of human G-17-I produced nearly constant plasma G-17 levels and acid secretory rates. Gastric volume equilibrated at approximately 80 ml during intragastric amino acid infusion and intragastric saline infusion (with or without i.v. G-17-I). Maintaining gastric pH at 5.0 prevented acid from entering the small intestine and stimulating release of at least some enterogastrones, such as secretin, which might inhibit acid secretion.
By infusing several doses of G-17-I intravenously during intragastric saline infusion, the relationship between plasma G-17 concentration and acid secretion could be defined in the presence of a standard degree of gastric distention. From this curve, the fraction of the acid secretory response to amino acids that could be attributed to endogenous G-17 release was determined. There were three possibilities. First (11, 12) . Both cholecystokinin and gastric inhibitory polypeptide, when given exogenously, can antagonize gastrin-stimulated acid secretion (13, 14) . 
